Background Subcutaneous administration of the monoclonal antibody L9LS protected adults
against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal …

Malaria remains one of the biggest health problems in the world. While significant reductions
in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend …

Malaria remains one of the most important infectious diseases in the world, with the greatest
burden in sub-Saharan Africa, primarily from Plasmodium falciparum infection. The …

Summary Background The R21/Matrix-M vaccine has demonstrated high efficacy against
Plasmodium falciparum clinical malaria in children in sub-Saharan Africa. Using trial data …

Background A blood-stage Plasmodium falciparum malaria vaccine would provide a second
line of defence to complement partially effective or waning immunity conferred by the …

Ensuring that malaria vaccines deliver maximum public health impact is non-trivial. Drawing
on current research, this article examines hurdles that malaria immunization may face to …

Malaria, caused by infection with Plasmodium parasites, drives multiple regulatory
responses across the immune landscape. These regulatory responses help to protect …

Die STIKO empfiehlt Reiseimpfungen zum individuellen Schutz Reisender mit einem
Expositionsrisiko gegenüber bestimmten impfpräventablen Erkrankungen und um den …

Cameroon introduced the malaria vaccine in its routine immunization program on 22
January 2024 in the 42 districts out of 200 that are among the most at risk of malaria. A cross …

Highlights•Symbionts of the mosquito vector are explored as interventions against vector-
borne diseases.•Viral infection of dipteran insects activates immune pathways that are …